Cancer Research Annual Meeting 2010  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Min, Y. H.
Right arrow Articles by Lee, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Min, Y. H.
Right arrow Articles by Lee, M. H.
[Cancer Research 64, 5225-5231, August 1, 2004]
© 2004 American Association for Cancer Research


Regular Articles

Cytoplasmic Mislocalization of p27Kip1 Protein Is Associated with Constitutive Phosphorylation of Akt or Protein Kinase B and Poor Prognosis in Acute Myelogenous Leukemia

Yoo Hong Min1,2, June-Won Cheong1, Ji Yeon Kim3, Ju In Eom3, Seung Tae Lee1, Jee Sook Hahn1, Yun Woong Ko1 and Mark Hong Lee4

1 Department of Internal Medicine; 2 Brain Korea 21 Project for Medical Science; 3 Clinical Research Center, Yonsei University College of Medicine; and 4 Department of Internal Medicine, Sungkyunkwan University College of Medicine, Seoul, Korea

Cyclin-dependent kinase inhibitor p27Kip1 functions at the nuclear level by binding to cyclin E/cyclin-dependent kinase-2. It was shown that Akt or protein kinase B (Akt/PKB)-dependent phosphorylation of p27Kip1 led to the cytoplasmic mislocalization of p27Kip1, suggesting the potential abrogation of its activity. Here, we evaluated the localization of p27Kip1 protein in leukemic blasts in relation to Akt/PKB phosphorylation and clinical outcomes in acute myelogenous leukemia (AML). Western blot analysis of the nuclear and cytoplasmic fractions revealed a heterogenous localization pattern of p27Kip1 in AML. Cytoplasmic mislocalization of p27Kip1 was significantly associated with the constitutive serine473 Akt/PKB phosphorylation in AML cells (P < 0.05). Transfection of U937 cells with an expression construct encoding the constitutively active form of Akt/PKB resulted in a remarkable increase in the levels of cytoplasmic p27Kip1. Whereas the transfection of U937 cells with a construct encoding dominant-negative Akt/PKB resulted in a recovery of nuclear localization of p27Kip1. Both the disease-free survival and overall survival are significantly shorter in AML cases with high cytoplasmic to nuclear ratio of p27Kip1 localization compared with the cases with low cytoplasmic to nuclear ratio (P = 0.0353, P = 0.0023, respectively). Multivariate analysis indicated that the cytoplasmic to nuclear ratio of p27Kip1 localization was an independent prognostic variable for both disease-free survival and overall survival (P = 0.043, P = 0.008, respectively). These findings additionally extend our understanding of the role of p27Kip1 in AML, and buttress the case of p27Kip1 mislocalization as a prognostic indicator and Akt/PKB/p27Kip1 pathway as a ready target for antileukemia therapy.




This article has been cited by other articles:


Home page
Cancer Res.Home page
J. G. Turner, D. C. Marchion, J. L. Dawson, M. F. Emmons, L. A. Hazlehurst, P. Washausen, and D. M. Sullivan
Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition
Cancer Res., September 1, 2009; 69(17): 6899 - 6905.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. D. Larrea, F. Hong, S. A. Wander, T. G. da Silva, D. Helfman, D. Lannigan, J. A. Smith, and J. M. Slingerland
RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility
PNAS, June 9, 2009; 106(23): 9268 - 9273.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
L. Salazar, T. Kashiwada, P. Krejci, P. Muchowski, D. Donoghue, W. R. Wilcox, and L. M. Thompson
A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells
Hum. Mol. Genet., June 1, 2009; 18(11): 1951 - 1961.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
C. E. Glover, K. E. Gurley, K.-H. Kim, B. Storer, M. L. Fero, and C. J. Kemp
Endocrine dysfunction in p27Kip1 deficient mice and susceptibility to Wnt-1 driven breast cancer
Carcinogenesis, June 1, 2009; 30(6): 1058 - 1063.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. Kazi, A. Carie, M. A. Blaskovich, C. Bucher, V. Thai, S. Moulder, H. Peng, D. Carrico, E. Pusateri, W. J. Pledger, et al.
Blockade of Protein Geranylgeranylation Inhibits Cdk2-Dependent p27Kip1 Phosphorylation on Thr187 and Accumulates p27Kip1 in the Nucleus: Implications for Breast Cancer Therapy
Mol. Cell. Biol., April 15, 2009; 29(8): 2254 - 2263.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
P. A Dennis
Targeting Akt in Cancer: Promise, Progress, and Potential Pitfalls
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 25 - 35.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Weisberg, L. Banerji, R. D. Wright, R. Barrett, A. Ray, D. Moreno, L. Catley, J. Jiang, E. Hall-Meyers, M. Sauveur-Michel, et al.
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells
Blood, April 1, 2008; 111(7): 3723 - 3734.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. S. Kim, J. I. Eom, J.-W. Cheong, A. J. Choi, J. K. Lee, W. I. Yang, and Y. H. Min
Protein Kinase CK2{alpha} as an Unfavorable Prognostic Marker and Novel Therapeutic Target in Acute Myeloid Leukemia
Clin. Cancer Res., February 1, 2007; 13(3): 1019 - 1028.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
U. Testa and R. Riccioni
Deregulation of apoptosis in acute myeloid leukemia
Haematologica, January 1, 2007; 92(1): 81 - 94.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. S. Suh, J. M. Crutchley, A. Koochek, A. Ryscavage, K. Bhat, T. Tanaka, A. Oshima, P. Fitzgerald, and S. H. Yuspa
Reciprocal Modifications of CLIC4 in Tumor Epithelium and Stroma Mark Malignant Progression of Multiple Human Cancers
Clin. Cancer Res., January 1, 2007; 13(1): 121 - 131.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. M. Kornblau, M. Womble, Y. H. Qiu, C. E. Jackson, W. Chen, M. Konopleva, E. H. Estey, and M. Andreeff
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia
Blood, October 1, 2006; 108(7): 2358 - 2365.
[Abstract] [Full Text] [PDF]


Home page
Plant Physiol.Home page
M. J. Jakoby, C. Weinl, S. Pusch, S. J.H. Kuijt, T. Merkle, N. Dissmeyer, and A. Schnittger
Analysis of the Subcellular Localization, Function, and Proteolytic Control of the Arabidopsis Cyclin-Dependent Kinase Inhibitor ICK1/KRP1
Plant Physiology, August 1, 2006; 141(4): 1293 - 1305.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis
Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway
Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Tsurutani, J. Fukuoka, H. Tsurutani, J. H. Shih, S. M. Hewitt, W. D. Travis, J. Jen, and P. A. Dennis
Evaluation of Two Phosphorylation Sites Improves the Prognostic Significance of Akt Activation in Non-Small-Cell Lung Cancer Tumors
J. Clin. Oncol., January 10, 2006; 24(2): 306 - 314.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
D. A. Haas-Kogan, M. D. Prados, T. Tihan, D. A. Eberhard, N. Jelluma, N. D. Arvold, R. Baumber, K. R. Lamborn, A. Kapadia, M. Malec, et al.
Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib
J Natl Cancer Inst, June 15, 2005; 97(12): 880 - 887.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.